OvaScience Inc (NASDAQ:OVAS) CEO Michelle Dipp purchased 59,700 shares of the stock in a transaction that occurred on Friday, March 18th. The shares were purchased at an average price of $8.26 per share, with a total value of $493,122.00. Following the completion of the acquisition, the chief executive officer now directly owns 971,921 shares in the company, valued at $8,028,067.46. The purchase was disclosed in a filing with the SEC, which is available through this link.
Michelle Dipp also recently made the following trade(s):
On Wednesday, March 16th, Michelle Dipp purchased 59,029 shares of OvaScience stock. The shares were purchased at an average price of $7.90 per share, with a total value of $466,329.10.
On Monday, March 14th, Michelle Dipp purchased 162,732 shares of OvaScience stock. The shares were purchased at an average price of $7.60 per share, with a total value of $1,236,763.20.
Shares of OvaScience Inc (NASDAQ:OVAS) traded up 6.52% on Monday, hitting $9.31. 138,650 shares of the company traded hands. The firm’s market capitalization is $253.98 million. The firm’s 50-day moving average is $6.49 and its 200 day moving average is $10.38. OvaScience Inc has a 1-year low of $4.53 and a 1-year high of $55.69.
OvaScience (NASDAQ:OVAS) last posted its earnings results on Thursday, February 25th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by $0.05. On average, analysts anticipate that OvaScience Inc will post ($2.79) earnings per share for the current fiscal year.
OVAS has been the subject of several research reports. Credit Suisse initiated coverage on shares of OvaScience in a report on Wednesday, January 20th. They issued an “underperform” rating for the company. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of OvaScience in a report on Wednesday, February 17th. Zacks Investment Research upgraded shares of OvaScience from a “sell” rating to a “hold” rating in a report on Saturday, January 9th. Finally, Oppenheimer lowered shares of OvaScience from an “outperform” rating to a “market perform” rating in a report on Monday, January 25th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $20.00.
An institutional investor recently raised its position in OvaScience stock. DIAM Co. Ltd. increased its position in shares of OvaScience Inc (NASDAQ:OVAS) by 0.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 296,434 shares of the company’s stock after buying an additional 2,209 shares during the period. DIAM Co. Ltd. owned about 1.09% of OvaScience worth $2,970,000 as of its most recent SEC filing.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of new fertility treatments based on egg precursor or EggPC cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries. With the Company’s AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the In vitro fertilization (NASDAQ:OVAS) process to supplement the existing mitochondria.
Source: American Banking and Market News